Systemic therapy in metastatic or recurrent endometrial cancer

Cancer Treatment Reviews

Volumn 33, Issue 2, 2007, Pages 177-190

  Pectasides, D ^a   Pectasides, E ^a   Economopoulos, T ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chemotherapy; Endocrine therapy; Endometrial carcinoma; Targeted agents

Indexed keywords

AMSACRINE; ANASTROZOLE; ARZOXIFENE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DIAZIQUONE; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GOSERELIN; HYDROXYPROGESTERONE CAPROATE; IFOSFAMIDE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ALOPECIA; ANEMIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; GYNECOLOGIC CANCER; HEMATOLOGIC DISEASE; HEMATURIA; HORMONAL THERAPY; HUMAN; INFECTION; LEUKOPENIA; LYMPHADENECTOMY; METASTASIS POTENTIAL; MONOTHERAPY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PAPILLARY CARCINOMA; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; SEPSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERUS CARCINOMA; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 33847369903     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.10.007     Document Type: Review

References (130)

1. Viser O., Coebergh J.W.W., Schouten L.J., and VanDijk J.A.A.M. Incidence of cancer in the Netherlands 1995 (1998), Netherlands Cancer Registry, Utrect p. 43
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
3. Gallup D.G., and Stock R.J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64 3 (1984) 417-420
4. Glassburn J.R. Carcinoma of the endometrium. Cancer 48 Suppl. 2 (1981) 575-581
5. Piver M.S., and Hempling R.E. A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer 66 6 (1990) 1133-1138
6. Stryker J.A., Podczaski E., Kaminski P., and Velkley D.E. Adjuvant external beam therapy for pathologic stage I and occult stage II endometrial carcinoma. Cancer 67 11 (1991) 2872-2879
7. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al., Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 3 (2004) 744-751
8. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355 9213 (2000) 1404-1411
9. Wylie J., Irwin C., Pintilie M., Levin W., Manchul L., Milosevic M., et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 77 1 (2000) 66-72
10. Nag S., Martinez-Monge R., Copeland L.J., Vacarello L., and Lewandowski G.S. Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina. Gynecol Oncol 66 1 (1997) 16-19
11. Goff B.A., Goodman A., Muntz H.G., Fuller Jr. A.F., Nikrui N., and Rice L.W. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 52 2 (1994) 237-240
12. Randall M.E., Spirtos N.M., and Dvoretsky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122. J Natl Cancer Inst Monogr 19 (1995) 13-15
13. Benedet J.L., Bender H., Jones III H., Ngan H.Y., and Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70 2 (2000) 209-262
14. Elit L., and Hirte H. Novel strategies for systemic treatment of endometrial cancer. Expert Opin Investig Drugs 9 12 (2000) 2831-2853
15. Macdonald R.R., Thorogood J., and Mason M.K. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 95 2 (1988) 166-174
16. Podratz K.C., O'Brien P.C., Malkasian Jr. G.D., Decker D.G., Jefferies J.A., and Edmonson J.H. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 66 1 (1985) 106-110
17. Piver M.S., Barlow J.J., Lurain J.R., and Blumenson L.E. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45 2 (1980) 268-272
18. Hirai Y., Hasumi K., Onose R., Kuramoto H., Kuzuya K., Hatae M., et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecol Oncol 94 2 (2004) 471-476
19. Scudder S.A., Liu P.Y., Wilczynski S.P., Smith H.O., Jiang C., Hallum III A.V., et al., Southwest Oncology Group. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol 96 3 (2005) 610-615
20. Fleming G.F., Fowler J.M., Waggoner S.E., Copeland L.J., Greer B.E., Horowitz I., et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 19 4 (2001) 1021-1029
21. Dimopoulos M.A., Papadimitriou C.A., Georgoulias V., Moulopoulos L.A., Aravantinos G., Gika D., et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78 1 (2000) 52-57
22. Deppe G., Malviya V.K., Malone J.M., Christensen C.W., and Saunders D. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol 15 4 (1994) 263-266
23. Barrett R.J., Blessing J.A., Homesley H.D., Twiggs L., and Webster K.D. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16 6 (1993) 494-496
24. Abeler V.M., Kjorstad K.E., and Berle E. Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 2 1 (1992) 9-22
25. Homesley H.D., and Zaino R. Endometrial cancer: prognostic factors. Semin Oncol 21 1 (1994) 71-78
26. Kosary C.L. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10 1 (1994) 31-46
27. Wolfson A.H., Sightler S.E., Markoe A.M., Schwade J.G., Averette H.E., Ganjei P., et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45 2 (1992) 142-146
28. Zaino R.J., Kurman R.J., Diana K.L., and Morrow C.P. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage-a Gynecologic Oncology Group study. Cancer 77 6 (1996) 1115-1121
29. Fleming GF. Systemic management of high-risk endometrial carcinoma. Educational book, 42nd ASCO annual meeting. p. 305-7.
30. Abeler V.M., and Kjorstad K.E. Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 39 3 (1990) 266-271
31. Carcangiu M.L., and Chambers J.T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47 3 (1992) 298-305
32. Ward B.G., Wright R.G., and Free K. Papillary carcinomas of the endometrium. Gynecol Oncol 39 3 (1990) 347-351
33. Chan J.K., Loizzi V., Youssef M., Osann K., Rutgers J., Vasilev S.A., et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 90 1 (2003) 181-185
34. Gallion H.H., van Nagell Jr. J.R., Powell D.F., Donaldson E.S., Higgins R.V., Kryscio R.J., et al. Stage I serous papillary carcinoma of the endometrium. Cancer 63 11 (1989) 2224-2228
35. Abeler V.M., Vergote I.B., Kjorstad K.E., and Trope C.G. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 78 8 (1996) 1740-1747
36. Webb G.A., and Lagios M.D. Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 156 6 (1987) 1486-1491
37. Alektiar K.M., McKee A., Lin O., Venkatraman E., Zelefsky M.J., McKee B., et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?. Int J Radiat Oncol Biol Phys 54 1 (2002) 79-85
38. Aquino-Parsons C., Lim P., Wong F., and Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 71 1 (1998) 83-86
39. Malpica A., Tornos C., Burke T.W., and Silva E.G. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 19 7 (1995) 769-774
40. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60 Suppl 8 (1987) 2035-2041
41. Boronow R.C., Morrow C.P., Creasman W.T., Disaia P.J., Silverberg S.G., Miller A., et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63 6 (1984) 825-832
42. Bucy G.S., Mendenhall W.M., Morgan L.S., Chafe W.E., Wilkinson E.J., Marcus Jr. R.B., et al. Clinical stage I and II endometrial carcinoma treated with surgery and/or radiation therapy: analysis of prognostic and treatment-related factors. Gynecol Oncol 33 3 (1989) 290-295
43. Gal D., Recio F.O., Zamurovic D., and Tancer M.L. Lymphvascular space involvement-a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 42 2 (1991) 142-145
44. Inoue Y., Obata K., Abe K., Ohmura G., Doh K., Yoshioka T., et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 78 7 (1996) 1447-1451
45. Sivridis E., Buckley C.H., and Fox H. The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol 94 10 (1987) 991-994
46. Grimshaw R.N., Tupper W.C., Fraser R.C., Tompkins M.G., and Jeffrey J.F. Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol 36 1 (1990) 97-100
47. Sutton G.P. The significance of positive peritoneal cytology in endometrial cancer. Oncology (Williston Park) 4 6 (1990) 21-26
48. Turner D.A., Gershenson D.M., Atkinson N., Sneige N., and Wharton A.T. The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 74 5 (1989) 775-780
49. Kadar N., Homesley H.D., and Malfetano J.H. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 46 2 (1992) 145-149
50. Elit L., and Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 14 1 (2002) 67-73
51. Reifenstein Jr. E.C. Hydroxyprogesterone caproate therapy in advanced endometrial cancer. Cancer 27 3 (1971) 485-502
52. Thigpen T., Blessing J., DiSaia P., et al. Oral medroxyprogesterone acetate in advanced or recurrent endometrial cancer: Results of therapy and correlation with estrogen and progesterone receptor levels-The Gynecologic Oncology Group experience. In: Baulier E., Iacobelli S., and McGuire W. (Eds). Endocrinology and malignancy (1986), Parthenon Publishers, Pearl River, NY 446-454
53. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 6 (1999) 1736-1744
54. Lentz S.S., Brady M.F., Major F.J., Reid G.C., and Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 14 2 (1996) 357-361
55. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., and Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19 2 (2001) 364-367
56. Rendina G.M., Donadio C., Fabri M., Mazzoni P., and Nazzicone P. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 17 4 (1984) 285-291
57. Pandya K.J., Yeap B.Y., Weiner L.M., Krook J.E., Erban J.K., Schinella R.A., et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol 24 1 (2001) 43-46
58. Fiorica J.V., Brunetto V.L., Hanjani P., Lentz S.S., Mannel R., Andersen W., and Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 1 (2004) 10-14
59. Whitney C.W., Brunetto V.L., Zaino R.J., Lentz S.S., Sorosky J., Armstrong D.K., et al., Gynecologic Oncology Group study. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 1 (2004) 4-9
60. Chan S. Arzoxifene in breast cancer. Eur J Cancer 38 Suppl. 6 (2002) S55-S56
61. McMeekin D.S., Gordon A., Fowler J., Melemed A., Buller R., Burke T., et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 90 1 (2003) 64-69
62. Gallagher C.J., Oliver R.T., Oram D.H., Fowler C.G., Blake P.R., Mantell B.S., et al. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 98 10 (1991) 1037-1041
63. De Vriese G., and Bonte J. Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers. Eur J Gynaecol Oncol 14 3 (1993) 187-191
64. Asbury R.F., Brunetto V.L., Lee R.B., Reid G., Rocereto T.F., and Gynecologic Oncology Group. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol 25 6 (2002) 557-560
65. Rose P.G., Brunetto V.L., VanLe L., Bell J., Walker J.L., and Lee R.B. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 78 2 (2000) 212-216
66. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 14 4 (2004) 650-658
67. Horton J., Begg C.B., Arseneault J., Bruckner H., Creech R., and Hahn R.G. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62 1 (1978) 159-161
68. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 12 7 (1994) 1408-1414
69. Calero F., Asins-Codoner E., Jimeno J., Rodriguez Escudero F., Mendana J., Iglesias J., et al. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Espanol para el Tratamiento Oncologico (GGETO). Eur J Cancer 27 7 (1991) 864-866
70. Muggia F.M., Blessing J.A., Sorosky J., and Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 20 9 (2002) 2360-2364
71. Escobar P.F., Markman M., Zanotti K., Webster K., and Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 129 11 (2003) 651-654
72. 2 every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 98 2 (2005) 294-298
73. Thigpen J.T., Blessing J.A., Homesley H., Creasman W.T., and Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 33 1 (1989) 68-70
74. Seski J.C., Edwards C.L., Herson J., and Rutledge F.N. Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 59 2 (1982) 225-228
75. Thigpen J.T., Blessing J.A., Lagasse L.D., DiSaia P.J., and Homesley H.D. Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 7 3 (1984) 253-256
76. Burke T.W., Munkarah A., Kavanagh J.J., Morris M., Levenback C., Tornos C., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 51 3 (1993) 397-400
77. Green III J.B., Green S., Alberts D.S., O'Toole R., Surwit E.A., and Noltimier J.W. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 75 4 (1990) 696-700
78. van Wijk F.H., Lhomme C., Bolis G., Scotto di Palumbo V., Tumolo S., Nooij M., et al., European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 39 1 (2003) 78-85
79. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88 3 (2003) 277-281
80. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62 2 (1996) 278-281
81. Wadler S., Levy D.E., Lincoln S.T., Soori G.S., Schink J.C., and Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 21 11 (2003) 2110-2114
82. Miller D.S., Blessing J.A., Lentz S.S., and Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 87 3 (2002) 247-251
83. Rose P.G., Gordon N.H., Fusco N., Fluellen L., Rodriguez M., Ingalls S.T., et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol Oncol 78 2 (2000) 228-234
84. Traina T.A., Sabbatini P., Aghajanian C., and Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 95 1 (2004) 235-241
85. Campora E., Vidali A., Mammoliti S., Ragni N., and Conte P.F. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide. Eur J Gynaecol Oncol 11 3 (1990) 181-183
86. Muggia F.M., Chia G., Reed L.J., and Romney S.L. Doxorubicin-cyclophosphamide: effective chemotherapy for advanced endometrial adenocarcinoma. Am J Obstet Gynecol 128 3 (1977) 314-319
87. Seski J.C., Edwards C.L., Gershenson D.M., and Copeland L.J. Doxorubicin and cyclophosphamide chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58 1 (1981) 88-91
88. Seltzer V., Vogl S.E., and Kaplan B.H. Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma. Gynecol Oncol 19 3 (1984) 308-313
89. Trope C., Johnsson J.E., Simonsen E., Christiansen H., Cavallin-Stahl E., and Horvath G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. Am J Obstet Gynecol 149 4 (1984) 379-381
90. Pasmantier M.W., Coleman M., Silver R.T., Mamaril A.P., Quiguyan C.C., and Galindo Jr. A. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer Treat Rep 69 5 (1985) 539-542
91. Edmonson J.H., Krook J.E., Hilton J.F., Malkasian G.D., Everson L.K., Jefferies J.A., et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28 1 (1987) 20-24
92. Burke T.W., Stringer C.A., Morris M., Freedman R.S., Gershenson D.M., Kavanagh J.J., et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40 3 (1991) 264-267
93. Dunton C.J., Pfeifer S.M., Braitman L.E., Morgan M.A., Carlson J.A., and Mikuta J.J. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 41 2 (1991) 113-116
94. Hancock K.C., Freedman R.S., Edwards C.L., and Rutledge F.N. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium. Cancer Treat Rep 70 6 (1986) 789-791
95. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22 19 (2004) 3902-3908
96. Aapro M.S., van Wijk F.H., Bolis G., Chevallier B., van der Burg M.E., Poveda A., et al., European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 3 (2003) 441-448
97. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19 20 (2001) 4048-4053
98. Akram T., Maseelall P., and Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 192 5 (2005) 1365-1367
99. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22 11 (2004) 2159-2166
100. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 8 (2004) 1173-1178
101. Polyzos N.P., Pavlidis N., Paraskevaidis E., and Ioannidis J.P. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer 42 3 (2006) 319-326
102. Carey M.S., Gawlik C., Fung-Kee-Fung M., Chambers A., Oliver T., and Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101 1 (2006) 158-167
103. Lovecchio J.L., Averette H.E., Lichtinger M., Townsend P.A., Girtanner R.W., and Fenton A.N. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate. Obstet Gynecol 63 4 (1984) 557-560
104. Hoffman M.S., Roberts W.S., Cavanagh D., Praphat H., Solomon P., and Lyman G.H. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. Gynecol Oncol 35 1 (1989) 75-77
105. Deppe G., Jacobs A.J., Bruckner H., and Cohen C.J. Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate. Am J Obstet Gynecol 140 3 (1981) 313-316
106. Bruckner H.W., and Deppe G. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. Obstet Gynecol 50 Suppl. 1 (1977) 10s-12s
107. Cohen C.J., Bruckner H.W., Deppe G., Blessing J.A., Homesley H., Lee J.H., et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstet Gynecol 63 5 (1984) 719-726
108. Horton J., Elson P., Gordon P., Hahn R., and Creech R. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer 49 12 (1982) 2441-2445
109. Ayoub J., Audet-Lapointe P., Methot Y., Hanley J., Beaulieu R., Chemaly R., et al. Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 31 2 (1988) 327-337
110. Santin A.D., Bellone S., Gokden M., Palmieri M., Dunn D., Agha J., et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8 5 (2002) 1271-1279
111. Santin A.D. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?. Gynecol Oncol 88 3 (2003) 263-265
112. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Gokden M., et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer 90 9 (2004) 1814-1824
113. Santin A.D., Zhan F., Cane' S., Bellone S., Palmieri M., Thomas M., et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 92 8 (2005) 1561-1573
114. Santin A.D., Bellone S., Siegel E.R., Palmieri M., Thomas M., Cannon M.J., et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 192 3 (2005) 813-818
115. Slomovitz B.M., Broaddus R.R., Burke T.W., Sneige N., Soliman P.T., Wu W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22 15 (2004) 3126-3132
116. Villella J.A., Cohen S., Tiersten A., Smith D.H., Hibshoosh H., and Hershman D. Her2/neu expression in uterine papillary serous cancers. Proc Am Soc Clin Oncol 22 (2004) 1870 [abstr]
117. Slomovitz B.M., Broaddus R.R., Schmandt R., Wu W., Oh J.C., Ramondetta L.M., et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 95 1 (2004) 32-36
118. Wolf J., and Slomovitz B.M. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer 15 (2005) 411
119. Jasas K.V., Fyles A., Elit L., Hoskins P.J., Biagi J., Dubuc-Lissoir J., et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. Proc Am Soc Clin Oncol 22 (2004) 5019 [abstr]
120. Leslie K.K., Laider L., Albitar L., et al. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer 15 (2005) 409-411
121. An H.J., Lee Y.H., Cho N.H., Shim J.Y., Kim J.Y., Lee C., et al. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p. 27. Histopathology 41 5 (2002) 437-445
122. Terakawa N., Kanamori Y., and Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10 2 (2003) 203-208
123. Slomovitz B.M., Wu W., Broaddus R.R., Soliman P.T., Wolf J., Sun C.C., et al. mTOR inhibition is a rational target for the treatment of endometrial cancer. Proc Am Soc Clin Oncol 22 (2004) 5076 [abstr]
124. Zhou C., Gehrig P.A., Whang Y.E., and Boggess J.F. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2 8 (2003) 789-795
125. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62 21 (2002) 6141-6145
126. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10 20 (2004) 7031-7042
127. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 6 (2005) 747-759
128. Oza A.M., Elit L., Biagi J., Chapman W., Tsao M., Hedley D., et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. Proc Am Soc Clin Oncol 24 (2006) 3003 [abstr]
129. Talvensaari-Mattila A., Soini Y., and Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol 26 2 (2005) 81-87
130. DeBernardo R.L., Littell R.D., Luo H., Duska L.R., Oliva E., Kirley S.D., et al. Defining the extent of cables loss in endometrial cancer subtypes and its effectiveness as an inhibitor of cell proliferation in malignant endometrial cells in vitro and in vivo. Cancer Biol Ther 4 1 (2005) 103-107